Please assess the completion status of the following clinical trial:

Trial Title: Ciprofloxacin for the Prevention of Meningococcal Meningitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Resident in a village included in the study area~Exclusion Criteria:~* Patients currently exhibiting symptoms of meningitis (to be immediately referred for further care)~* Persons with a known allergy to fluoroquinolone antibiotics.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard care (Type: NO_INTERVENTION): No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
- Household prophylaxis (Type: ACTIVE_COMPARATOR): Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age \>12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age \<3 months: 75 mg (1.5 ml oral suspension).
- Village prophylaxis (Type: ACTIVE_COMPARATOR): Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age \>12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age \<3 months: 75 mg (1.5 ml oral suspension).

Based on this trial design, predict the completion outcome and termination type (if applicable).